Related Experiment Video

Updated: Jun 3, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Recent advances in the discovery of small molecule mTOR inhibitors

Abhijit Roychowdhury1, Rajiv Sharma, Sanjay Kumar

  • 1Department of Medicinal Chemistry, Piramal Life Sciences Limited, 1 Nirlon, Off Western Express Highway, Goregaon (E) Mumbai, India.

Future Medicinal Chemistry
|March 24, 2011
PubMed

Insights

Mammalian target of rapamycin (mTOR) regulates metabolism and is a key therapeutic target for diseases like cancer. This review focuses on mTOR inhibitors, particularly nonrapamycin-based small molecules, and their selectivity.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Mammalian target of rapamycin (mTOR) is a master regulator of cellular metabolism, controlling the balance between catabolic and anabolic processes.
  • mTOR is implicated in various diseases, including cancer, inflammation, and metabolic disorders, making it a significant therapeutic target.
  • mTOR functions centrally within the PI3K/AKT/PDK1 signaling pathway.

Purpose of the Study:

  • To provide a comprehensive overview of selective and nonselective mTOR inhibitors.
  • To emphasize nonrapamycin-based small-molecule inhibitors and their impact on mTOR selectivity.
  • To discuss the clinical significance of mTOR-selective inhibitors versus broader PI3K/AKT/mTOR inhibitors.

Main Methods:

  • Literature review focusing on mTOR inhibitors.
  • Analysis of selective and nonselective mTOR inhibitors.
  • Examination of nonrapamycin-based small-molecule inhibitors and their selectivity profiles.

Main Results:

  • Recent development of mTOR-selective inhibitors with over 1000-fold selectivity against PI3K has been achieved.
  • The review highlights various small-molecule inhibitors targeting mTOR.
  • Emphasis is placed on modulating mTOR selectivity through nonrapamycin-based compounds.

Conclusions:

  • The development of selective mTOR inhibitors represents a significant advancement in targeted therapy.
  • The clinical utility of highly selective mTOR inhibitors compared to broader PI3K/AKT/mTOR inhibitors remains an area of active investigation.
  • Further research is needed to determine the optimal therapeutic strategy involving mTOR inhibition.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...